KYMR Relative Valuation
KYMR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, KYMR is overvalued; if below, it's undervalued.
Historical Valuation
Kymera Therapeutics Inc (KYMR) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -16.71. The fair price of Kymera Therapeutics Inc (KYMR) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 66.23 USD , Kymera Therapeutics Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：66.23
Fair
Undervalued
-17.49
PE
1Y
3Y
5Y
Trailing
Forward
-9.43
EV/EBITDA
Kymera Therapeutics Inc. (KYMR) has a current EV/EBITDA of -9.43. The 5-year average EV/EBITDA is -14.51. The thresholds are as follows: Strongly Undervalued below -47.56, Undervalued between -47.56 and -31.03, Fairly Valued between 2.01 and -31.03, Overvalued between 2.01 and 18.53, and Strongly Overvalued above 18.53. The current Forward EV/EBITDA of -9.43 falls within the Historic Trend Line -Fairly Valued range.
-10.41
EV/EBIT
Kymera Therapeutics Inc. (KYMR) has a current EV/EBIT of -10.41. The 5-year average EV/EBIT is -10.99. The thresholds are as follows: Strongly Undervalued below -34.78, Undervalued between -34.78 and -22.89, Fairly Valued between 0.90 and -22.89, Overvalued between 0.90 and 12.80, and Strongly Overvalued above 12.80. The current Forward EV/EBIT of -10.41 falls within the Historic Trend Line -Fairly Valued range.
102.34
PS
Kymera Therapeutics Inc. (KYMR) has a current PS of 102.34. The 5-year average PS is 35.17. The thresholds are as follows: Strongly Undervalued below -0.72, Undervalued between -0.72 and 17.22, Fairly Valued between 53.11 and 17.22, Overvalued between 53.11 and 71.06, and Strongly Overvalued above 71.06. The current Forward PS of 102.34 falls within the Strongly Overvalued range.
-18.96
P/OCF
Kymera Therapeutics Inc. (KYMR) has a current P/OCF of -18.96. The 5-year average P/OCF is -28.15. The thresholds are as follows: Strongly Undervalued below -111.52, Undervalued between -111.52 and -69.83, Fairly Valued between 13.54 and -69.83, Overvalued between 13.54 and 55.23, and Strongly Overvalued above 55.23. The current Forward P/OCF of -18.96 falls within the Historic Trend Line -Fairly Valued range.
-16.82
P/FCF
Kymera Therapeutics Inc. (KYMR) has a current P/FCF of -16.82. The 5-year average P/FCF is -17.49. The thresholds are as follows: Strongly Undervalued below -46.39, Undervalued between -46.39 and -31.94, Fairly Valued between -3.04 and -31.94, Overvalued between -3.04 and 11.41, and Strongly Overvalued above 11.41. The current Forward P/FCF of -16.82 falls within the Historic Trend Line -Fairly Valued range.
Kymera Therapeutics Inc (KYMR) has a current Price-to-Book (P/B) ratio of 5.02. Compared to its 3-year average P/B ratio of 3.37 , the current P/B ratio is approximately 48.80% higher. Relative to its 5-year average P/B ratio of 4.48, the current P/B ratio is about 12.08% higher. Kymera Therapeutics Inc (KYMR) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -9.24%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -7.21% , the current FCF yield is about -100.00% lower.
5.02
P/B
Median3y
3.37
Median5y
4.48
-4.85
FCF Yield
Median3y
-9.24
Median5y
-7.21
Competitors Valuation Multiple
The average P/S ratio for KYMR's competitors is 1.79, providing a benchmark for relative valuation. Kymera Therapeutics Inc Corp (KYMR) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of -26.12%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of KYMR increased by 64.63% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -1.67K to -2.97K.
The secondary factor is the P/E Change, contributed 12.76%to the performance.
Overall, the performance of KYMR in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Kymera Therapeutics Inc (KYMR) currently overvalued or undervalued?
What is Kymera Therapeutics Inc (KYMR) fair value?
How does KYMR's valuation metrics compare to the industry average?
What is the current P/B ratio for Kymera Therapeutics Inc (KYMR) as of Dec 05 2025?
What is the current FCF Yield for Kymera Therapeutics Inc (KYMR) as of Dec 05 2025?
What is the current Forward P/E ratio for Kymera Therapeutics Inc (KYMR) as of Dec 05 2025?